• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Clinical Ophthalmology (Auckland N.Z.) >The clinical utility of new combination phenylephrine/ketorolac injection in cataract surgery
【2h】

The clinical utility of new combination phenylephrine/ketorolac injection in cataract surgery

机译：苯肾上腺素/酮咯酸联合注射液在白内障手术中的临床应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The maintenance of mydriasis throughout cataract extraction surgery and the control of ocular inflammation are crucial for successful surgical outcomes. The development of miosis during cataract surgery compromises the visualization of the surgical field and working space for surgeons. This may lead to complications that include posterior capsular tear and associated vitreous loss, longer surgical time, and postoperative inflammation. Postoperative inflammation is often uncomfortable and frustrating for patients. It causes pain, redness, and photophobia. This compromises the best-uncorrected vision following surgery and often leads to multiple clinic visits. This article examines the literature published on the current treatments used to manage mydriasis, pain, and inflammation in cataract extraction surgery. Combination phenylephrine/ketorolac injection offers an exciting new class of medication for use in cataract surgery. With the recent approval of Omidria™ (combination of phenylephrine 1% and ketorolac 0.3%) by the US Food and Drug Administration (FDA) for intraocular use, we review the clinical utility of this new combination injection in cataract surgery. PubMed, MEDLINE, and conference proceedings were searched for the relevant literature using a combination of the following search terms: cataract extraction surgery, pupil dilation (mydriasis), miosis, phenylephrine, ketorolac, Omidria™, intracameral mydriatic. Relevant articles were reviewed and their references checked for further relevant literature. All abstracts were reviewed and full texts retrieved where available.
机译：白内障摘除手术期间散瞳的维持和眼部炎症的控制对于成功的手术结果至关重要。白内障手术期间瞳孔缩小的发展损害了手术视野和外科医生的工作空间。这可能导致并发症，包括后囊撕裂和相关的玻璃体丢失，更长的手术时间以及术后炎症。术后炎症通常使患者不舒服并且令人沮丧。它会引起疼痛，发红和畏光。这损害了手术后最佳的未矫正视力，并经常导致多次就诊。本文研究了有关白内障摘除手术中用于控制瞳孔散大，疼痛和炎症的当前治疗方法的文献。苯肾上腺素/酮咯酸联合注射剂为白内障手术提供了令人兴奋的新型药物。在美国食品药品监督管理局（FDA）最近批准Omidria™（1％的去氧肾上腺素和0.3％的酮咯酸的组合）用于眼内使用之后，我们对这种新组合注射剂在白内障手术中的临床实用性进行了综述。使用以下搜索词的组合对PubMed，MEDLINE和会议程序进行了搜索，以寻找相关文献：白内障摘除手术，瞳孔散大（瞳孔散大），瞳孔缩小，去氧肾上腺素，酮咯酸，Omidria™，前房内散瞳。审查了相关文章，并检查了其参考文献以获取更多相关文献。对所有摘要进行了审查，并在可用的情况下检索了全文。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号